

Richard A Hubner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5785002/publications.pdf>

Version: 2024-02-01

57
papers

2,512
citations

304743

22
h-index

197818

49
g-index

57
all docs

57
docs citations

57
times ranked

4559
citing authors

#	ARTICLE	IF	CITATIONS
1	A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. <i>Nature Genetics</i> , 2007, 39, 984-988.	21.4	754
2	Second-line chemotherapy in advanced biliary cancer: a systematic review. <i>Annals of Oncology</i> , 2014, 25, 2328-2338.	1.2	279
3	Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 894-904.	10.7	270
4	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 200-210.	6.3	90
5	<i>MTHFR</i> C677T and colorectal cancer risk: A meta-analysis of 25 populations. <i>International Journal of Cancer</i> , 2007, 120, 1027-1035.	5.1	88
6	Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations. <i>PLoS ONE</i> , 2011, 6, e25164.	2.5	77
7	¹⁸ F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 115-129.	3.7	76
8	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , 2020, 84, 101936.	7.7	73
9	Folate and colorectal cancer prevention. <i>British Journal of Cancer</i> , 2009, 100, 233-239.	6.4	62
10	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. <i>Cancer Treatment Reviews</i> , 2020, 89, 102084.	7.7	61
11	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102258.	7.7	45
12	Ornithine Decarboxylase G316A Genotype Is Prognostic for Colorectal Adenoma Recurrence and Predicts Efficacy of Aspirin Chemoprevention. <i>Clinical Cancer Research</i> , 2008, 14, 2303-2309.	7.0	43
13	Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence. <i>Neuroendocrinology</i> , 2016, 103, 500-517.	2.5	41
14	Genetic Variants of <i>UGT1A6</i> Influence Risk of Colorectal Adenoma Recurrence. <i>Clinical Cancer Research</i> , 2006, 12, 6585-6589.	7.0	40
15	Folate Metabolism Polymorphisms Influence Risk of Colorectal Adenoma Recurrence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1607-1613.	2.5	36
16	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. <i>Scientific Reports</i> , 2019, 9, 11610.	3.3	36
17	Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. <i>Cancer Treatment Reviews</i> , 2014, 40, 1230-1238.	7.7	34
18	Molecular advances in medullary thyroid cancer diagnostics. <i>Clinica Chimica Acta</i> , 2006, 370, 2-8.	1.1	29

#	ARTICLE	IF	CITATIONS
19	Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence. <i>International Journal of Cancer</i> , 2008, 123, 586-593.	5.1	29
20	MTHFR C677T has differential influence on risk of MSI and MSS colorectal cancer. <i>Human Molecular Genetics</i> , 2007, 16, 1072-1077.	2.9	28
21	Should folic acid fortification be mandatory? No. <i>BMJ: British Medical Journal</i> , 2007, 334, 1253-1253.	2.3	28
22	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw277.	6.3	28
23	In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat. <i>Journal of Hypertension</i> , 2001, 19, 941-946.	0.5	22
24	Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. <i>Endocrine-Related Cancer</i> , 2014, 21, R485-R493.	3.1	22
25	Thymidylate synthase polymorphisms, folate and B-vitamin intake, and risk of colorectal adenoma. <i>British Journal of Cancer</i> , 2007, 97, 1449-1456.	6.4	20
26	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. <i>Current Oncology Reports</i> , 2017, 19, 50.	4.0	17
27	Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat. <i>Clinical Science</i> , 2003, 105, 339-345.	4.3	16
28	The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3779.	3.7	16
29	Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial. <i>International Journal of Cancer</i> , 2007, 121, 2001-2004.	5.1	14
30	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. <i>PLoS ONE</i> , 2018, 13, e0206007.	2.5	14
31	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 1682-1688.	1.1	13
32	Gemcitabine Plus Capecitabine in Unselected Patients With Advanced Pancreatic Cancer. <i>Pancreas</i> , 2013, 42, 511-515.	1.1	9
33	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). <i>Clinical and Translational Oncology</i> , 2019, 21, 950-953.	2.4	9
34	NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4005-4005.	1.6	9
35	Single Nucleotide Polymorphisms and Cancer Susceptibility. , 2017, , 231-239.		8
36	Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease. <i>Current Hypertension Reports</i> , 2001, 3, S31-S33.	3.5	7

#	ARTICLE	IF	CITATIONS
37	Re: MLH1 93G>A Promoter Polymorphism and the Risk of Microsatellite-Unstable Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1490-1490.	6.3	7
38	Influence of co-morbidity on renal function assessment by Cockcroft&Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy. <i>Lung Cancer</i> , 2011, 73, 356-360.	2.0	7
39	Sunitinib for advanced pancreatic neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1817-1827.	2.4	7
40	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 975-983.	4.1	7
41	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 94, 102168.	7.7	6
42	Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. <i>Oncologist</i> , 2022, 27, 97-103.	3.7	6
43	Fibrolamellar carcinoma: Challenging the challenge. <i>European Journal of Cancer</i> , 2020, 137, 144-147.	2.8	5
44	Ivosidenib: an investigational drug for the treatment of biliary tract cancers. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 301-307.	4.1	5
45	Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy. <i>Acta Oncologica</i> , 2022, 61, 583-590.	1.8	4
46	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 101, 102299.	7.7	3
47	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1198-1208.	1.0	3
48	Combined hepatocellular&cholangiocarcinoma " More questions than answers. <i>Liver International</i> , 2021, 41, 1186-1188.	3.9	2
49	Polymorphic Variation and Risk of Colorectal Cancer. , 2010, , 147-171.		2
50	Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1009-1015.	2.4	2
51	Reply to the letter to the editor "Second-line chemotherapy in advanced biliary cancer: the present now will later be past" by Vivaldi et al.. <i>Annals of Oncology</i> , 2014, 25, 2444-2445.	1.2	1
52	To BRCA or Not to PALB. <i>Journal of Clinical Oncology</i> , 2015, 33, 2581-2582.	1.6	1
53	Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
54	Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency (PEI) in patients with advanced pancreatic cancer (aPC): PanDA.. <i>Journal of Clinical Oncology</i> , 2021, 39, 196-196.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Chemoprevention. , 2011, , 209-226.		0
56	Clinical Management of Targeted Therapies in Neuroendocrine Tumours. , 2014, , 141-154.		0
57	Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy.. Journal of Clinical Oncology, 2022, 40, 475-475.	1.6	0